2 completed, 1 unknown. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow APO-go: new trials by email Literature Review of APO-go trials Research Report on APO-go
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes APL-130277, APO-go, Apokyn - Parkinson Disease | Phase 2 | Completed | Sumitomo Pharma America, Inc. | 8 | 2017-08-22 | 2020-08-13 |
| Apomorphine in Parkinson's Disease Patients With Visual Hallucinations Apomorphine, Placebo - Parkinson's Disease, Hallucinations, Visual | Phase 2 | Unknown | University Medical Center Groningen | 35 | 2017-05-01 | 2017-05-03 |
| Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease Apomorphine hydrochloride, Placebo - Parkinson's Disease | Phase 3 | Completed | Britannia Pharmaceuticals Ltd. | 107 | 2014-03-03 | 2019-07-08 |
Parkinson Disease (3) · Hallucinations (1)
Britannia Pharmaceuticals Ltd. (1) · Sumitomo Pharma America, Inc. (1) · University Medical Center Groningen (1)
Netherlands (2) · Austria (1) · Denmark (1) · France (1) · Germany (1) · Spain (1) · United Kingdom (1) · United States (1)
Regina Katzenschlager, Doz. Dr. (1) · Teus van Laar, MD PhD (1)
PMID 18442107, PMID 18591063, PMID 19524477, PMID 19740486, PMID 20962287, PMID 21921019, PMID 23934921, PMID 25382161, PMID 26474316, PMID 26709292, PMID 30055903, PMID 33486139, PMID 33991326